Genital Diseases, Female  >>  irinotecan  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
irinotecan / Generic mfg.
NCT00003345: Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Completed
2
35
US
cisplatin, irinotecan hydrochloride
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
10/01
10/01
NCT00053833: S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Terminated
2
2
US, Canada
irinotecan, camptosar
Southwest Oncology Group, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
07/04
07/04
NCT00136955: Irinotecan Study For Cervical Cancer

Completed
2
41
RoW
Irinotecan
Pfizer
Uterine Cervical Neoplasms
05/08
05/08
NCT01091259: Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2
29
US
Irinotecan, Camptosar, CPT-11, Bevacizumab, Avastin
NYU Langone Health, Genentech, Inc.
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
02/14
05/15

Download Options